hy-n2019 Search Results


chaetocin  (MedChemExpress)
94
MedChemExpress chaetocin
Suppressing H3K9me3 potentiates WYC‐209 inhibition of tumor metastasis. A) Schematic of the experimental protocol; i.v., intravenous injection. Control B16‐F1 cells were cultured in 90 Pa fibrin gels for 5 days to form TRCs. TRCs were isolated from gels and injected intravenously via tail veins into wild‐type immune‐competent syngeneic C57BL/6 mice at 100 000 cells per mouse. Various groups: 8 mice per group were injected with TRCs for 5 days and then were treated with DMSO (0.1%, vehicle) or molecules every 2 days via intravenous injection. Mice were dissected on day 30 or on the day of death to examine signs of lung metastases. B) Lung metastases of B16‐F1 TRCs after being treated with WYC‐209, <t>chaetocin,</t> WYC‐209 with chaetocin, JIB‐04, JIB‐04 with WYC‐209, or DMSO. * p < 0.05; *** p < 0.001 with Fisher's exact test. C) Survival ratio of C57BL/6 mice injected with TRCs treated with different molecules. Statistical analyses of survival ratio were performed by Mantel–Cox test (ns = not significantly different; ** p < 0.01; *** p < 0.001 compared to DMSO‐treated group). Note that on day 30 all mice from the DMSO group, chaetocin alone group, and JIB‐04 alone group died; the three lines from three groups overlap, so one only could see the red line. None of the mice from the WYC‐209 0.11 mg kg −1 + chaetocin 0.013 mg kg −1 group and WYC‐209 0.22 mg kg −1 died on day 30; the two lines from two groups overlap, so one only could see the blue line.
Chaetocin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-n2019/Chaetocin/pmc09631059-215-2-19
Average 94 stars, based on 1 article reviews
chaetocin - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Suppressing H3K9me3 potentiates WYC‐209 inhibition of tumor metastasis. A) Schematic of the experimental protocol; i.v., intravenous injection. Control B16‐F1 cells were cultured in 90 Pa fibrin gels for 5 days to form TRCs. TRCs were isolated from gels and injected intravenously via tail veins into wild‐type immune‐competent syngeneic C57BL/6 mice at 100 000 cells per mouse. Various groups: 8 mice per group were injected with TRCs for 5 days and then were treated with DMSO (0.1%, vehicle) or molecules every 2 days via intravenous injection. Mice were dissected on day 30 or on the day of death to examine signs of lung metastases. B) Lung metastases of B16‐F1 TRCs after being treated with WYC‐209, chaetocin, WYC‐209 with chaetocin, JIB‐04, JIB‐04 with WYC‐209, or DMSO. * p < 0.05; *** p < 0.001 with Fisher's exact test. C) Survival ratio of C57BL/6 mice injected with TRCs treated with different molecules. Statistical analyses of survival ratio were performed by Mantel–Cox test (ns = not significantly different; ** p < 0.01; *** p < 0.001 compared to DMSO‐treated group). Note that on day 30 all mice from the DMSO group, chaetocin alone group, and JIB‐04 alone group died; the three lines from three groups overlap, so one only could see the red line. None of the mice from the WYC‐209 0.11 mg kg −1 + chaetocin 0.013 mg kg −1 group and WYC‐209 0.22 mg kg −1 died on day 30; the two lines from two groups overlap, so one only could see the blue line.

Journal: Advanced Science

Article Title: Synthetic Retinoid Kills Drug‐Resistant Cancer Stem Cells via Inducing RAR γ ‐Translocation‐Mediated Tension Reduction and Chromatin Decondensation

doi: 10.1002/advs.202203173

Figure Lengend Snippet: Suppressing H3K9me3 potentiates WYC‐209 inhibition of tumor metastasis. A) Schematic of the experimental protocol; i.v., intravenous injection. Control B16‐F1 cells were cultured in 90 Pa fibrin gels for 5 days to form TRCs. TRCs were isolated from gels and injected intravenously via tail veins into wild‐type immune‐competent syngeneic C57BL/6 mice at 100 000 cells per mouse. Various groups: 8 mice per group were injected with TRCs for 5 days and then were treated with DMSO (0.1%, vehicle) or molecules every 2 days via intravenous injection. Mice were dissected on day 30 or on the day of death to examine signs of lung metastases. B) Lung metastases of B16‐F1 TRCs after being treated with WYC‐209, chaetocin, WYC‐209 with chaetocin, JIB‐04, JIB‐04 with WYC‐209, or DMSO. * p < 0.05; *** p < 0.001 with Fisher's exact test. C) Survival ratio of C57BL/6 mice injected with TRCs treated with different molecules. Statistical analyses of survival ratio were performed by Mantel–Cox test (ns = not significantly different; ** p < 0.01; *** p < 0.001 compared to DMSO‐treated group). Note that on day 30 all mice from the DMSO group, chaetocin alone group, and JIB‐04 alone group died; the three lines from three groups overlap, so one only could see the red line. None of the mice from the WYC‐209 0.11 mg kg −1 + chaetocin 0.013 mg kg −1 group and WYC‐209 0.22 mg kg −1 died on day 30; the two lines from two groups overlap, so one only could see the blue line.

Article Snippet: JIB‐04 (HY‐13953), chaetocin (HY‐N2019), lysophosphatidic acid (HY‐137862), ML‐7 (HY‐15417), trichostatin A (HY‐15144), and latrunculin A (HY‐16929) were obtained from MedChem Express (NJ, USA).

Techniques: Inhibition, Injection, Control, Cell Culture, Isolation